Table 2 All interventions identified to potentially modify OHSS risk
Interventions | Systematic review with meta-analysis |
|---|---|
Alternative hCG protocol |  ✖ |
Aspirin |  ✖ |
Calcium infusion |  ✔ |
Carbegoline |  ✔ |
Clomiphene citrate |  ✔ |
Coasting |  ✔ |
Corifollitropin alfa |  ✔ |
Cycle cancellation |  ✖ |
Diosmin |  ✔ |
Dopaminergic agonists |  ✔ |
Dual trigger |  ✖ |
Elective cryopreservation |  ✔ |
Elective single embryo transfer (e-SET) |  ✖ |
Follitropin delta |  ✖ |
FSH dose decrease |  ✖ |
Glucocorticoid |  ✔ |
GnRH analogs |  ✔ |
Inositol |  ✖ |
Insulin sensitizing drugs |  ✖ |
In vitro maturation of oocytes |  ✔ |
Intensified luteal phase support with hCG |  ✖ |
Intensified luteal phase support: GnRH agonist |  ✔ |
Ketoconazole |  ✖ |
Kisspeptin |  ✖ |
Letrozole |  ✔ |
LH addition |  ✔ |
Luteal GnRH antagonist administration |  ✖ |
Luteal phase support / GnRH agonist |  ✔ |
Luteal phase support / hCG |  ✔ |
Luteal phase support / progesterone |  ✔ |
Melatonin |  ✔ |
Metformin |  ✔ |
Mild ovarian stimulation |  ✔ |
Monitoring and surveillance |  ✔ |
Natural IVF cycles |  ✔ |
Oral contraceptives |  ✔ |
Ovarian drilling |  ✔ |
Personalization |  ✔ |
Predictive models |  ✔ |
Progestin-primed ovarian stimulation |  ✔ |
Triggering / hCG dose |  ✖ |
Triggering / GnRH agonist |  ✔ |
Triggering / r-hLH |  ✔ |
Triggering / hCG type |  ✔ |
Gonadotropins |  ✔ |
Vitamin D |  ✖ |
Volume expanders / albumin |  ✔ |
Volume expanders / hydroxyethyl starch |  ✔ |